Telix Pharmaceuticals Ltd — Capital/Financing Update 2024

Jun 26, 2024

Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [156 x 65] intentionally omitted <==

27 June 2024

Notice under section 708A(5)(e) of the Corporations Act 2001 Telix Pharmaceuticals Limited (ASX Code: TLX) (“Company”)

Reference is made to the Appendix 2A released on 27 June 2024 and the issue of fully paid ordinary shares in Telix Pharmaceuticals Limited (“Shares”). For the purposes of section 708A(5)(e) of the Corporations Act, the Company gives notice that:

• (a) The Company issued Shares upon the exercise of unlisted Share Options as follows:

Date of issue	Shares issued	Options exercised
21/06/2024	104,500	104,500
Total	104,500	104,500

• (b) The Company issued the shares without disclosure under part 6D.2 of the Corporations Act;

• (c) As at the date of this notice the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act; and

• (d) As at the date of this notice there is no information which is “excluded information” (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

Authorised for release by

==> picture [123 x 36] intentionally omitted <==

Genevieve Ryan Company Secretary

Page 1